Biogen Q3 GAAP loss $0.47/sh, revenue $2.53B; updates FY guidance, highlights LEQEMBI

BIOGEN INC.

2023-Q3 EPS reported $6.26 revenue$7,449,300,000

Revenue $2.53B (+1% YoY, +3% CC); GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36 (-9% YoY).
LEQEMBI FDA approval for Alzheimer's, ZURZUVAE for PPD approved; Reata acquisition closed.
Fit for Growth cost savings program of $1B initiated to improve bottom line.
Full-year 2023 guidance updated; new launches expected to drive growth.
Subcutaneous LEQEMBI and tau-directed ASO (BIIB080) show clinical potential.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOGEN INC. reported third quarter ended September 30, 2023 results: revenue $2,530 million, EPS GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36.

Period: third quarter ended September 30, 2023
Revenue: $2,530 million
EPS: GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36
Result: reported results

Exact text from the filing

--- EX-99.1 (EX-99.1) --- Press Release Cambridge, Mass. – Nov. 8, 2023 Biogen reports third quarter 2023 results and updates full year 2023 guidance Third quarter revenue $2,530 million; GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36 Poised for leadership in Alzheimer's disease with ongoing LEQEMBI launch and development of tau-directed ASO (BIIB080) • New

View on SEC.gov

Browse all earnings releases →

BIOGEN INC. filing history →

Source: SEC EDGAR

accession 0000875045-23-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.